May - תוצאות חיפוש

רומניה - רומנית - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

physioneal 40 glucoza 38,6 mg/ml

baxter healthcare sa - irlanda - combinatii - sol. pt. dial. perit. - 38,6g/l - preparate pentru dializa peritoneala solutii hipertone

רומניה - רומנית - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

botox 50 unitati allergan

allergan pharmaceuticals ireland - toxina botulinica de tip a - pulb. pt. sol. inj. - 50unitati - miorelaxante periferice alte miorelaxante cu actiune periferica

רומניה - רומנית - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

botox 100 unitati allergan

allergan pharmaceuticals ireland - toxina botulinica de tip a - pulb. pt. sol. inj. - 100unitati - miorelaxante periferice alte miorelaxante cu actiune periferica

רומניה - רומנית - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

botox 200 unitati allergan

allergan pharmaceuticals ireland - toxina botulinica de tip a - pulb. pt. sol. inj. - 200unitati - miorelaxante periferice alte miorelaxante cu actiune periferica

האיחוד האירופי - רומנית - EMA (European Medicines Agency)

yervoy

bristol-myers squibb pharma eeig - ipilimumab - melanoma; carcinoma, renal cell; carcinoma, non-small-cell lung; mesothelioma, malignant; colorectal neoplasms - agenți antineoplazici - melanomayervoy as monotherapy or combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (see section 4. yervoy in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. relative to nivolumab monotherapy, an increase in progression-free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression (see sections 4. 4 și 5. renal cell carcinoma (rcc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5. non-small cell lung cancer (nsclc)yervoy in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. malignant pleural mesothelioma (mpm)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)yervoy in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy (see section 5. oesophageal squamous cell carcinoma (oscc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%.